Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
78 hedge funds and large institutions have $50.2M invested in Aralez Pharmaceuticals Inc. in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 12 closing their positions.
68% more call options, than puts
Call options by funds: $677K | Put options by funds: $403K
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
6% less funds holding
Funds holding: 83 → 78 (-5)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
61% less capital invested
Capital invested by funds: $128M → $50.2M (-$77.6M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.43M |
| 2 |
BC
Broadfin Capital
New York
|
+$1.5M |
| 3 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$1.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$735K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$545K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TLCM
Tiger Legatus Capital Management
New York
|
-$8.75M |
| 2 |
AC
Armistice Capital
New York
|
-$8.03M |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$4.69M |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$2.54M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$665K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
76
OrbiMed
New York
| – | -$301K | -68,143 | Closed |
|
|
CS
77
Credit Suisse
Zurich,
Switzerland
| – | -$251K | -56,875 | Closed |
|
|
JGC
78
J. Goldman & Co
New York
| – | -$198K | -45,000 | Closed |
|
|
AG
79
Algert Global
San Francisco,
California
| – | -$187K | -42,407 | Closed |
|
|
DMK
80
David M. Knott
| – | -$166K | -37,698 | Closed |
|
81
D.E. Shaw & Co
New York
| – | -$166K | -37,621 | Closed |
|
|
DTL
82
Dynamic Technology Lab
Singapore
| – | -$103K | -23,391 | Closed |
|
|
TCIM
83
TIAA CREF Investment Management
New York
| – | -$69K | -15,610 | Closed |
|
|
TC
84
TFS Capital
West Chester,
Pennsylvania
| – | -$66K | -15,031 | Closed |
|
ARLZ Hedge Fund Activity: Q1 2017 in Review
78 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q1 2017, worth a combined $50.2M — down 61% from $128M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARLZ and 9 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was BlackRock, opening a new position worth an estimated $3.43M. The largest seller was Tiger Legatus Capital Management, exiting entirely with an estimated $8.75M sold.
- 78 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q1 2017, down from 83 in Q4 2016.
- Funds reported $50.2M of Aralez Pharmaceuticals Inc. stock for Q1 2017, down 61% quarter-over-quarter.
- 9 funds opened new Aralez Pharmaceuticals Inc. positions in Q1 2017 and 12 closed out, a net change of -3 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q1 2017 was BlackRock, an estimated $3.43M added.
- The largest Aralez Pharmaceuticals Inc. seller in Q1 2017 was Tiger Legatus Capital Management, an estimated $8.75M sold.
Based on aggregated 13F filings for Q1 2017.